Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
Shankar Siva, MBBS, PhD, FRANZCR
Advertisement
Articles by Shankar Siva, MBBS, PhD, FRANZCR
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
3
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
4
Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care
5